Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_3
1
20%
Ph not_applicable
3
60%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
Terminated2
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (20.0%)
Phase 31 (20.0%)
N/A3 (60.0%)

Trials by Status

completed240%
suspended120%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
completednot_applicable

Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer

NCT02132845
completedphase_2

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

NCT02094872
terminatednot_applicable

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT02132884
terminatednot_applicable

Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer

NCT03049358
suspendedphase_3

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00324831

Clinical Trials (5)

Showing 5 of 5 trials
NCT02132845Not Applicable

Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer

Completed
NCT02094872Phase 2

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

Completed
NCT02132884Not Applicable

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Terminated
NCT03049358Not Applicable

Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer

Terminated
NCT00324831Phase 3

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Suspended

All 5 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
5